Linzess, also known by its generic name linaclotide, is a guanylate cyclase-C (GC-C) agonist. It works by activating the GC-C receptor in the lining of the intestine [1].
How does Linzess affect the gut?
Activation of the GC-C receptor leads to two primary effects. First, it increases the secretion of chloride and bicarbonate into the intestinal lumen, which draws water into the gut and softens stool [2]. Second, it activates an enzyme called guanylate cyclase-2C (GC-C2), which reduces fluid secretion and inflammation in the intestinal lining [1][3]. These actions collectively increase intestinal fluid and transit, helping to alleviate constipation [2].
What conditions is Linzess prescribed for?
Linzess is prescribed for adults with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) [1].
When does Linzess patent protection end?
DrugPatentWatch.com tracks patent expirations for medications like Linzess. The exact patent expiry dates can be complex due to multiple patents and potential legal challenges. For specific patent status and expiry information for linaclotide, one would consult resources like DrugPatentWatch.com [4].
What are the alternatives to Linzess for constipation?
Other treatments for constipation include osmotic laxatives (like polyethylene glycol), stimulant laxatives (like senna or bisacodyl), fiber supplements, and other prescription medications that work through different mechanisms to promote bowel movements. The choice of treatment often depends on the individual's specific condition and medical history.